EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

Xiao-Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Nancy Agrawal, Janet Hammond

The Journal of Clinical Pharmacology · 2026

DOI: 10.1002/jcph.70114 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Clinical Pharmacology, 2026. Verfasst von Xiao-Jian Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Atea Pharmaceuticals, Inc., Boston, MA, USA. Hauptthemen laut MEDLINE: ATP-Binding Cassette Transporters. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies. Bemnifosbuvir was demonstrated in vitro as a substrate and inhibitor of the ABC transporters’ P‐glycoprotein (P‐gp), as an inhibitor of the breast cancer resistance protein (BCRP), as well as a weak inhibitor of SLC transporters, including organic anion transporting polypeptide 1B1 (OATP1B1). Phase 1 studies in healthy participants were subsequently conducted to assess the clinical significance of transporter‐mediated DDI potentials of bemnifosbuvir as a precipitant using digoxin and rosuvastatin as P‐gp and BCRP/OATP1B1 index substrates, respectively. A single dose of 0.25 mg digoxin or 10 mg rosuvastatin was administered alone and with 1100 mg bemnifosbuvir, either simultaneously or staggered. Simultaneous administration of a single dose of 1100 mg bemnifosbuvir increased total plasma exposure of both drugs by less than 20%, and transiently increased the peak plasma exposure of digoxin and rosuvastatin by 78% and 40%, respectively. Staggered dosing reduced the magnitude of changes in peak exposure to digoxin and rosuvastatin. No serious adverse events or drug discontinuations were observed. Dose adjustments are therefore unlikely for drugs that are substrates of P‐gp or BCRP/OAT1B1 when coadministered with bemnifosbuvir, and staggered dosing may further reduce any DDI risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP-Binding Cassette TransportersHumansDrug InteractionsRosuvastatin CalciumFemaleMaleAdultATP Binding Cassette Transporter, Subfamily G, Member 2DigoxinMiddle AgedNeoplasm ProteinsLiver-Specific Organic Anion Transporter 1Young AdultATP Binding Cassette Transporter, Subfamily B, Member 1SulfonamidesPyrimidines

Stichwörter der Autor:innen

BCRPOATP1B1P‐gpbemnifosbuvirdrug–drug interactions

Substanzen

Rosuvastatin CalciumATP Binding Cassette Transporter, Subfamily G, Member 2DigoxinABCG2 protein, humanNeoplasm ProteinsATP-Binding Cassette TransportersLiver-Specific Organic Anion Transporter 1ATP Binding Cassette Transporter, Subfamily B, Member 1SLCO1B1 protein, humanSulfonamides

Autor:innen und Institutionen

  • Atea Pharmaceuticals, Inc., Boston, MA, USA.
  • Altasciences Company, Inc., Quebec, Canada.

Zitieren

APA

Zhou, X. J., Vo, A., Morelli, G., Montrond, M., Lynch, S., Pietropaolo, K., Belanger, B., Horga, A., Agrawal, N., & Hammond, J. (2026). In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.70114

Vancouver

Zhou XJ, Vo A, Morelli G, Montrond M, Lynch S, Pietropaolo K, et al. In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters. The Journal of Clinical Pharmacology. 2026. doi:10.1002/jcph.70114

BibTeX
@article{Zhou2026,
  author = {Zhou, Xiao-Jian and Vo, Alex and Morelli, Gaetano and Montrond, Maureen and Lynch, Shannan and Pietropaolo, Keith and Belanger, Bruce and Horga, Arantxa and Agrawal, Nancy and Hammond, Janet},
  title = {In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/jcph.70114}
}
Kostenlos starten →